Joint Development and Out-Licensing of Biosimilars with Chiome Bioscience
First written in FY2025-H1. 4 of 5 entries say "Advanced", first in FY2025. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In October of the same year, Alfresa Holdings, the Company and Chiome concluded a memorandum of basic agreement and other agreements concerning future joint development of new biosimilars, and construction of cell lines for multiple biosimilars is currently progressing smoothly.」
The development of new biosimilars with Chiome and MBI progressed to a basic agreement including Alfresa Holdings, and reached the stage at which cell-line construction for multiple products is under way. - 2026-05-14AdvancedEarnings presentation materials
「Alfresa Holdings, Chiome and the company entered into a basic agreement for the joint development of novel biosimilars (October 2025).」
A basic agreement was entered into with Alfresa Holdings and Chiome for the development of novel biosimilars. - FY2026-H1AdvancedAnnual report
「In October of the same year, Alfresa Holdings, the Company and Chiome concluded a memorandum of basic agreement for future joint development of new biosimilars and a basic agreement to promote the joint development of products for which cell-line construction is already under way. This clarified the roles of each company, including Alfresa Holdings, in developing new biosimilars with a view to commercial manufacturing at the domestic manufacturing facility to be developed under the grant-funded project, and development activities are now being accelerated. Under the basic agreement among the 3 companies, the Company and Chiome will receive consideration from Alfresa Holdings for cell-line construction.」
The development of new biosimilars with Chiome and MBI progressed to basic agreements and a basic memorandum of understanding joined by Alfresa Holdings, establishing a framework under which consideration for cell-line construction will be received. - FY2025AdvancedAnnual report
「In May 2025, we entered into a Master Service Agreement with Chiome and MBI and began constructing cell lines for the novel biosimilar.」
The business partnership with Chiome progressed to the execution of a Master Service Agreement incorporating MBI and the commencement of construction of a new biosimilar cell line. - FY2025-H1First statedAnnual report
「In June 2024, the Company concluded a business partnership agreement concerning biosimilar development with Chiome Bioscience Inc., which has strengths in the development of new antibody drugs.」
Through its business partnership with Chiome, the Company launched a collaborative model combining the two companies' personnel and development expertise to jointly develop cell lines and manufacturing processes, and share profits from out-licensing, transfers and development support.